FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2080946978> ?p ?o ?g. }

• W2080946978 abstract "Proceedings: AACR 103rd Annual Meeting 2012‐‐ Mar 31‐Apr 4, 2012; Chicago, ILRNAi technology has brought a new category of treatments for cancer. NFκB is a transcription factor which can inhibit apoptosis and promote cell proliferation. Activation of NFκB is linked to the progression of various cancers. Inhibition of NFκB and its downstream targets using NFκB-siRNA (NS) for cancer therapy has been investigated. However, for successful siRNA delivery, it has to be delivered into the cytoplasm of cancer cells. Naked siRNA is prone to degradation and has a plasma half-life of less than five minutes. In addition, the relatively small size of the siRNA leads to rapid renal clearance. These facts, together with the negatively charged siRNA which limits permeability across cell membrane, mean that successful delivery of naked siRNA is unlikely. Cationic lipid based systems have emerged as the most attractive siRNA delivery, however the use is limited due to poor transfection efficiency and toxicity. The use of polymers (polyethyleneimines and polyesteramines) has been hampered due to substantial toxicity. Natural polymer based delivery systems (chitosan, gelatin, albumin) are biocompatible and biodegradable with high physiological tolerance and low immunogenicity. The purpose of this study was to develop NS loaded into gelatin nanocarriers (NS-GNCs) that enables effective delivery in a targeted fashion to tumors. The NS-GNCs were prepared using cationic gelatin by desolvation method. The NS-GNCs were characterized for size, charge, entrapment, release and in vitro efficacy against lung and breast cancer cells. The size and zeta potential was found to be 180 ± 4 nm and 16 ± 2 mV respectively. Entrapment efficiency was found to be 81 ± 1.4 % and the release of siRNA was in a controlled manner up to 48 h. The dose dependent in vitro efficacy of NS-GNCs was studied using A549 lung cancer and MDA-MB-231 breast cancer cells compared to naked NS using untreated cells as a control. NS-GNCs showed significantly (p<0.05) higher cytotoxicity against lung and breast cancer cells in a dose dependant manner compared to naked NS. At 30ng/ml, NS-GNCs treated A549 cells showed 46% cytotoxicity compared to 16% in naked NS treated A549 cells. At 60ng/ml, NS-GNCs treated MDA-MB-231 cells showed 54% cytotoxicity compared to 21% in naked NS treated cells. The increased cytotoxicity with NS-GNCs can be attributed to the tumor specific accumulation of positively charged GNCs by uptake through electrochemical diffusion. Moreover, NS-GNCs showed comparable cytotoxicity as compared to lipofectamine (tranfecting agent) in both the cancer cells. The developed targeted NS-GNCs showed enhanced activity compared to naked NS against cancer cells. This innovative delivery approach will help to overcome the limitations and adverse side effects associated with current delivery approaches. We are currently investigating NS-GNC conjugation with RGD peptide to enhance the tumor specific delivery via receptor mediated endocytosis.Citation Format: {Authors}. {Abstract title} [abstract]. In: Proceedings of the 103rd Annual Meeting of the American Association for Cancer Research; 2012 Mar 31-Apr 4; Chicago, IL. Philadelphia (PA): AACR; Cancer Res 2012;72(8 Suppl):Abstract nr 5644. doi:1538-7445.AM2012-5644" @default.
• W2080946978 created "2016-06-24" @default.
• W2080946978 creator A5006163196 @default.
• W2080946978 creator A5012678680 @default.
• W2080946978 creator A5020072116 @default.
• W2080946978 creator A5034224781 @default.
• W2080946978 date "2012-04-15" @default.
• W2080946978 modified "2023-09-27" @default.
• W2080946978 title "Abstract 5644: Targeted nanocarriers of siRNA for the treatment of cancer" @default.
• W2080946978 doi "https://doi.org/10.1158/1538-7445.am2012-5644" @default.
• W2080946978 hasPublicationYear "2012" @default.
• W2080946978 type Work @default.
• W2080946978 sameAs 2080946978 @default.
• W2080946978 citedByCount "0" @default.
• W2080946978 crossrefType "proceedings-article" @default.
• W2080946978 hasAuthorship W2080946978A5006163196 @default.
• W2080946978 hasAuthorship W2080946978A5012678680 @default.
• W2080946978 hasAuthorship W2080946978A5020072116 @default.
• W2080946978 hasAuthorship W2080946978A5034224781 @default.
• W2080946978 hasConcept C104317684 @default.
• W2080946978 hasConcept C121608353 @default.
• W2080946978 hasConcept C126322002 @default.
• W2080946978 hasConcept C18150654 @default.
• W2080946978 hasConcept C185592680 @default.
• W2080946978 hasConcept C190283241 @default.
• W2080946978 hasConcept C22615655 @default.
• W2080946978 hasConcept C2780035454 @default.
• W2080946978 hasConcept C502942594 @default.
• W2080946978 hasConcept C54009773 @default.
• W2080946978 hasConcept C55493867 @default.
• W2080946978 hasConcept C71924100 @default.
• W2080946978 hasConcept C96232424 @default.
• W2080946978 hasConcept C98274493 @default.
• W2080946978 hasConceptScore W2080946978C104317684 @default.
• W2080946978 hasConceptScore W2080946978C121608353 @default.
• W2080946978 hasConceptScore W2080946978C126322002 @default.
• W2080946978 hasConceptScore W2080946978C18150654 @default.
• W2080946978 hasConceptScore W2080946978C185592680 @default.
• W2080946978 hasConceptScore W2080946978C190283241 @default.
• W2080946978 hasConceptScore W2080946978C22615655 @default.
• W2080946978 hasConceptScore W2080946978C2780035454 @default.
• W2080946978 hasConceptScore W2080946978C502942594 @default.
• W2080946978 hasConceptScore W2080946978C54009773 @default.
• W2080946978 hasConceptScore W2080946978C55493867 @default.
• W2080946978 hasConceptScore W2080946978C71924100 @default.
• W2080946978 hasConceptScore W2080946978C96232424 @default.
• W2080946978 hasConceptScore W2080946978C98274493 @default.
• W2080946978 hasLocation W20809469781 @default.
• W2080946978 hasOpenAccess W2080946978 @default.
• W2080946978 hasPrimaryLocation W20809469781 @default.
• W2080946978 hasRelatedWork W1970660459 @default.
• W2080946978 hasRelatedWork W1977528153 @default.
• W2080946978 hasRelatedWork W2037431694 @default.
• W2080946978 hasRelatedWork W2328272413 @default.
• W2080946978 hasRelatedWork W2330299153 @default.
• W2080946978 hasRelatedWork W2387285990 @default.
• W2080946978 hasRelatedWork W2465224281 @default.
• W2080946978 hasRelatedWork W2526371533 @default.
• W2080946978 hasRelatedWork W2530101166 @default.
• W2080946978 hasRelatedWork W2602090237 @default.
• W2080946978 hasRelatedWork W2738523285 @default.
• W2080946978 hasRelatedWork W2784133301 @default.
• W2080946978 hasRelatedWork W2796548286 @default.
• W2080946978 hasRelatedWork W2810672411 @default.
• W2080946978 hasRelatedWork W2811088957 @default.
• W2080946978 hasRelatedWork W2885433168 @default.
• W2080946978 hasRelatedWork W2957312781 @default.
• W2080946978 hasRelatedWork W2983556597 @default.
• W2080946978 hasRelatedWork W3181127299 @default.
• W2080946978 hasRelatedWork W3184269199 @default.
• W2080946978 isParatext "false" @default.
• W2080946978 isRetracted "false" @default.
• W2080946978 magId "2080946978" @default.
• W2080946978 workType "article" @default.